First: what actually determines pill effectiveness
Across the cagrilintide clinical program, the dominant tolerability issues have been gastrointestinal: nausea, reduced appetite, constipation, and, less commonly, vomiting a profile shared with pramlintide and with GLP-1 agonists, and mechanistically expected from a compound that slows the stomach and engages the area postrema
The data on those features are pretty new and still pretty small, but they're enticing in the sense that this class of drugs affects a lot of the way our hypothalamus functions in terms of modulating drives and impulses, in addition to the direct anti-obesity and metabolic benefits of the drugs
The article also discusses the evolving evidence on GLP-1s and mental health, noting that while some studies have reported reductions in depressive symptoms, data remain limited and careful patient selection is still recommended